Namodenoson Provided Clinical Stabilization as a Potential Bridge to Transplant in Advanced Liver Failure Ramat Gan, Israel, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: ...

This case describes a presentation of a patient with clinical features of acromegaly, elevated growth hormone (GH) concentrations, a pituitary adenoma but with normal insulin-like growth factor-1 (IGF ...

Please provide your email address to receive an email when new articles are posted on . Nearly 80% of patients with cirrhosis awaiting liver transplant reported clinically significant pain. Pain, ...

Around 13% of patients with a dementia diagnosis may instead have advanced liver disease — also called cirrhosis — which can cause reversible cognitive decline, researchers at the Virginia ...

Please provide your email address to receive an email when new articles are posted on . Patients with PBC and cirrhosis treated with seladelpar exhibited greater reductions in ALP, GGT and ALT at 12 ...

SGLT2 inhibitors were associated with significantly lower risks of kidney failure, cardiovascular events, mortality, and hepatic decompensation.

Ramat Gan, Israel, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and ...

AKI — Increase in serum creatinine ≥0.3 mg/dl within 48 hr or increase ≥1.5 times baseline level Increase in serum creatinine ≥0.3 mg/dl within 48 hr or increase ≥1.5 times baseline level, which is ...

The addition of SGLT2 inhibitors was associated with a nearly one third lower incidence of serious liver events in individuals with cirrhosis who were receiving diuretic therapy, a large cohort study ...

Ramat Gan, Israel, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs ...